On Friday the Supreme Court agreed to hear a case that threatens to kill securities class actions. Petitioners in Halliburton Co. v. Erica P. John Fund, Inc. have asked the Court to reconsider a quarter-century-old precedent that has served as
After much anticipation, the U.S. Food and Drug Administration (FDA) has taken action to place responsibility on generic drug manufacturers to provide adequate warnings to consumers, and hold them legally liable for their failure to do so. Currently, federal law
In Reed Elsevier, Inc. v. Crockett, Case No. 12-3574, the United States Court of Appeals for the Sixth Circuit struck yet another blow to consumers whose contracts of adhesion force arbitration of any disputes. Prior to Crockett, in some cases,
The story of banking giant JPMorgan Chase’s $13 billion settlement has been in heavy rotation on network and cable news outlets this week, as it should be. This settlement is the largest ever between a single company and the U.S.
The problem is familiar: a party fails to preserve some document or thing that would have been discoverable under the Rules, and possible evidence is lost. Years ago, these spoliation of evidence disputes arose most often in accident litigation, such
Yesterday, the New York Times published an interesting article regarding discount brokerage firm Charles Schwab & Company’s attempt to lessen (if not effectively eliminate) its exposure to liability for widespread investment related abuses. More specifically, in 2011, Schwab added a
I just finished a book about our profession at its very best. The book is Devil in the Grove, by Gilbert King. A 2013 Pulitzer Prize winner for Non-Fiction, Devil in the Grove tells the story of a criminal trial